טוען...
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing
The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient's leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect p...
שמור ב:
| הוצא לאור ב: | Mol Ther Methods Clin Dev |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Gene & Cell Therapy
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7917474/ https://ncbi.nlm.nih.gov/pubmed/33718517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2021.02.002 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|